Negative pressure wound treatment apparatus and infection identification system and method

Information

  • Patent Grant
  • 7799004
  • Patent Number
    7,799,004
  • Date Filed
    Monday, March 4, 2002
    23 years ago
  • Date Issued
    Tuesday, September 21, 2010
    14 years ago
Abstract
A vacuum assisted wound closure device having a means for identifying infectious agents within a wound site. The vacuum assisted wound closure device includes a screen for placement within a wound site, a sealing means for covering the wound site, and a vacuum source in fluid communication with the screen. A canister may be disposed between the screen and vacuum source, such that fluids or other exudates that may be drawn from the wound during application of negative pressure by the vacuum source are collected in the canister for later disposal. A sensing device, which may be a gas chromatograph, sensor array, or other similar device capable of optically sensing the presence of a bacterial agent or other form of infection being drawn from the wound site, is disposed within the screen or interposed between the screen and the vacuum source.
Description
FIELD OF THE INVENTION

The present invention relates to vacuum assisted wound treatment systems and methods, and more particularly to vacuum assisted wound treatment systems and methods that utilize a means for identifying infection through the use of optical analysis.


BACKGROUND OF THE INVENTION

Vacuum induced healing of open wounds has recently been popularized by Kinetic Concepts, Inc. of San Antonio, Tex., by its commercially available V.A.C.® product line. The vacuum induced healing process has been described in commonly assigned U.S. Pat. No. 4,969,880 issued on Nov. 13, 1990 to Zamierowski, as well as its continuations and continuations in part, U.S. Pat. No. 5,100,396, issued on Mar. 31, 1992, U.S. Pat. No. 5,261,893, issued Nov. 16, 1993, and U.S. Pat. No. 5,527,293, issued Jun. 18, 1996, the disclosures of which are incorporated herein by this reference. Further improvements and modifications of the vacuum induced healing process are also described in U.S. Pat. No. 6,071,267, issued on Jun. 6, 2000 to Zamierowski and U.S. Pat. Nos. 5,636,643 and 5,645,081 issued to Argenta et al. on Jun. 10, 1997 and Jul. 8, 1997 respectively, the disclosures of which are incorporated by reference as though fully set forth herein.


These patents, and others, addressed the problems associated with closure of many types of wounds, including large or infected wounds. Wound closure typically involves the migration of epithelial and subcutaneous tissue towards the center of the wound site. In many wounds however, this migration is slowed or non-existent due to the size of the wound, and the degree of infection. Such wounds have been commonly closed using sutures or staples, with varying results. Improved techniques, as those described in the above mentioned patents, involve applying a negative pressure to the wound over an area sufficient to promote migration of epithelial and subcutaneous tissue toward the wound. Such techniques have been met with extremely positive results, and are currently being marketed and utilized by a device known as V.A.C.® (Vacuum Assisted Closure™), manufactured by Kinetic Concepts, Incorporated, of San Antonio, Tex.


One difficulty associated with the use of the V.A.C.® device, is that no suitable means for detecting the presence or kind of infection present in the wound is available, without disturbing the airtight dressing covering the wound.


Substantial work has been performed relating to the detection of microorganisms, which include spectrometers, chromatographs, and other electronic sensors for detecting the presence of microorganisms. Exemplary U.S. patents known to applicant include Lewis, et al. U.S. Pat. No. 6,017,440 issued Jan. 25, 2000; Chutjian, et al. U.S. Pat. No. 6,188,067 issued Feb. 13, 2001; Hunter, et al. U.S. Pat. No. 5,811,255 issued Sep. 22, 1998; Overton, et al. U.S. Pat. No. 5,611,846 issued Mar. 18, 1997; and Yu U.S. Pat. No. 5,583,281 issued Dec. 10, 1996; the disclosures of which are incorporated by reference herein.


As is well known to those of ordinary skill in the art, closure of surface wounds involves the inward migration of epithelial and subcutaneous tissue adjacent the wound. This migration is ordinarily assisted through the inflammatory process, whereby blood flow is increased and various functional cell types are activated. Through the inflammatory process, blood flow through damaged or broken vessels is stopped by capillary level occlusion; thereafter, cleanup and rebuilding operations may begin. Unfortunately, this process is hampered when a wound is large or has become infected. In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the tissues) forms near the surface of the wound.


Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but also are also less able to successfully fight bacterial infection and thus are less able to naturally close the wound. Until the advent of vacuum induced therapy, such difficult wounds were addressed only through the use of sutures or staples. Although still widely practiced and sometimes effective, such mechanical closure techniques suffer a major disadvantage in that they produce tension on the skin tissue adjacent the wound. In particular, the tensile force required in order to achieve closure using sutures or staples may cause very high localized stresses at the suture or staple insertion point. These stresses commonly result in the rupture of the tissue at the insertion points, which can eventually cause wound dehiscence and additional tissue loss.


Additionally, some wounds harden and inflame to such a degree due to infection that closure by stapling or suturing is not feasible. Wounds not reparable by suturing or stapling generally require prolonged hospitalization, with its attendant high cost, and major surgical procedures, such as grafts of surrounding tissues. Examples of wounds not readily treatable with staples or suturing include large, deep, open wounds; decubitus ulcers; ulcers resulting from chronic osteomyelitis; and partial thickness burns that subsequently develop into full thickness burns.


As a result of these and other shortcomings of mechanical closure devices, methods and apparatus for draining wounds by applying continuous negative pressures have been developed. When applied over a sufficient area of the wound, such negative pressures have been found to promote the migration toward the wound of epithelial and subcutaneous tissues. In practice, the application to a wound of negative gauge pressure, commercialized by Assignee or its parent under the designation “Vacuum Assisted Closure” (or “V.A.C.®”) therapy, typically involves the mechanical-like contraction of the wound with simultaneous removal of excess fluid. In this manner, V.A.C.® therapy augments the body's natural inflammatory process while alleviating many of the known intrinsic side effects, such as the production of edema caused by increased blood flow absent the necessary vascular structure for proper venous return.


While V.A.C.® therapy has been highly successful in the promotion of wound closure, healing many wounds previously thought untreatable, some difficulty remains. Because the very nature of V.A.C.® therapy dictates an atmospherically sealed wound site, it is difficult to detect the presence or concentration of contaminant microorganisms, such as bacteria, that may be present in the wound site, without removing the wound dressing. It has heretofore been necessary to disturb the wound site, and thereby interrupt the therapy, in order to test for the presence or concentration of bacterial infection. Furthermore, any disturbance to the wound site may increase the possibility of infection to the wound site. Additionally, removal of the wound dressing may cause pain or discomfort to the patient.


Accordingly, a primary object of the present invention is to provide a vacuum assisted closure device that utilizes a means for detecting the presence of an infection present at a wound site during utilization of an airtight dressing, without disturbing the dressing at the wound site.


A further object of the present invention is to provide a means for identifying the nature or specific type of infection present at a wound site during the utilization of an airtight dressing, without disturbing the dressing at the wound site.


It is yet a further object of the present invention to provide a means for detecting the concentration of an infecting agent present at a wound site during utilization of an airtight dressing, without disturbing the dressing at the wound site.


SUMMARY OF THE INVENTION

In accordance with the foregoing objects, the present invention generally comprises a foam pad for insertion substantially into a wound site and a wound drape for sealing enclosure of the foam pad at the wound site. The foam pad, comprised of a foam having relatively few open cells in contact with the areas upon which cell growth is to be encouraged so as to avoid unwanted adhesions, but having sufficiently numerous open cells so that drainage and V.A.C.® therapy may continue unimpaired, is placed in fluid communication with a vacuum source for promotion of fluid drainage, as known in the art. Such communication may include a flexible tubing that is removably connected to the foam pad and the vacuum source. A connection adapter, sometimes referred to as an “elbow” adapter, an example of which is disclosed in FIG. 6 of international patent application PCT/GB96/02802 filed Nov. 14, 1996 by Heaton, et al., claiming priority to UK patent application GB2307180, filed Nov. 14, 1995, which reference is incorporated herein as though fully set forth, may be utilized to connect the flexible tubing to the wound dressing.


An infection detection means is connectable to the vacuum source, such that fluids being removed from the wound site will pass through the detection means during suction. The detection means is preferably positioned between the canister utilized to collect wound fluids in the traditional V.A.C.® and the vacuum source. However, it is to be understood that the detection means may be positioned anywhere along the line of suction from the wound site, so long as any filtration of the wound fluid occurs after passage of the fluid through the detection means.


The infection detection means is preferably comprised of an optical scanner that is capable of detecting changes in the frequency of light passing through the scanner. The frequency changes are identifiable to a particular bacterium, antigen, or other identifying source of infection. Alternative sensors include pH sensors for detecting changes in acidic concentrations of fluids being removed from the wound site during administration of negative pressure at the wound site.


Various types of detection devices may be utilized to detect the presence, concentration, and/or type of infection present in the wound site. Exemplary devices that may be utilized include those disclosed in the previously mentioned patents issued to Chutjan et al., Lewis et al., Hunter et al., and Overton et al.


Finally, many other features, objects and advantages of the present invention will be apparent to those of ordinary skill in the relevant arts, especially in light of the foregoing discussions and the following drawings and exemplary detailed description.





BRIEF DESCRIPTION OF THE DRAWINGS

Although the scope of the present invention is much broader than any particular embodiment, a detailed description of the preferred embodiment follows together with illustrative figures, wherein like reference numerals refer to like components, and wherein:



FIG. 1 shows, in schematic diagram, the preferred embodiment of the present invention as applied to a mammalian wound site.



FIG. 2 is a block diagram of the preferred sensor arrangement of the present invention as applied to the wound closure device of the present invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Although those of ordinary skill in the art will readily recognize many alternative embodiments, especially in light of the illustrations provided herein, this detailed description is exemplary of the preferred embodiment of the present invention, the scope of which is limited only by the claims that may be drawn hereto.


Referring now to the figures, and to FIG. 1 in particular, the present invention 10 is shown to generally comprise a foam pad 11, or other screen means, for insertion substantially into a wound site and a sealing means, such as a wound drape (not shown), for sealing enclosure of the foam pad 11 at the wound site. Flexible tubing 12 may be utilized to fluidically connect the foam pad 11 to a vacuum source 14. The vacuum source 14, which may encompasses a vacuum pump 15 and the sensing device, which may be comprised of a gas chromatograph 16. An exemplary gas chromatograph that may be utilized is disclosed in U.S. Pat. No. 5,611,846 issued to Overton, et al. on Mar. 18, 1997, which disclosure is incorporated herein as though fully set forth. In the preferred embodiment, photo diodes 18 are utilized in conjunction with the gas chromatograph to detect changes in light frequency as the fluid being pumped from the wound site passes across the photo diodes 18. The gas chromatograph 16 identifies the changes in frequency, which may be associated with particular bacteria or antigens. Light frequencies associated with such microorganisms are stored in a database within a computer-processing unit 20. A software program compares the frequencies detected by the gas chromatograph 16 with the frequencies stored in the database. If the software identifies a match in the frequencies detected by the chromatograph 16 with that of the microorganism frequencies stored in the database, an audible and/or visual notification is transmitted through the display 22.


As will be understood by those skilled in the art, alternate sensing devices may also be utilized for detecting the presence of microorganisms in the fluid being suctioned from the wound site by the vacuum pump 15. Examples of such alternate sensing devices include, but are not limited to miniature mass spectrometers, such as that described by Chutjan, et al. in U.S. Pat. No. 6,188,067 whose disclosure is incorporated herein by reference as though fully set forth. An alternate embodiment of the present invention may utilize sensor arrays similar to those described by Lewis, et al. in U.S. Pat. No. 6,017,440, whose disclosure is incorporated herein by reference as though fully set forth. Such a sensor array utilizes sensors comprised of regions of nonconducting organic material and regions of conducting organic material compositionally different than that of the nonconducting material.


The preferred sequential arrangement of the component parts of a V.A.C.® device utilizing the present invention is illustrated in FIG. 2. Such a device includes a foam pad 11 and screen means 13, such as an airtight dressing for application at the wound site. A conduit, such as flexible tubing 12, may be utilized to communicate fluids to and from the vacuum source 14, which houses a vacuum pump 15 as the source of the suction. However, it is to be understood that other means of suction may be utilized in alternative embodiments, including wall suction and other similar means. A canister 17 is connectable to the tubing 12 to capture and store fluids and other exudates extracted from the wound site during suction. The sensor 19, as described above in relation to FIG. 1, is preferably positioned between the canister 17 and the vacuum pump 15. Alternative embodiments, not shown, may allow positioning of the sensor 19 at other positions, including within the canister 17 itself, within the foam 11, dressing 13, or along the tubing 12. Additionally, automatic sampling lines may be utilized. Such positioning arrangements are dependent on the type of sensor utilized, and the limitations placed upon it due to its size and accuracy fluctuations due to direct contact with the wound fluids. The greatest accuracy lies, however, in placing the sensor 19 between the wound site and any filtration mechanisms that may be in place, which may include a hydrophobic filter or charcoal filter 23 located at the vacuum exhaust 24. A bleed orifice 25 may also be utilized to reduce the build up of excess pressure within the system.


While the foregoing description is exemplary of the preferred embodiment of the present invention, those of ordinary skill in the relevant arts will recognize the many variations, alterations, modifications, substitutions and the like are readily possible, especially in light of this description and the accompanying drawings. In any case, because the scope of the present invention is much broader than any particular embodiment, the foregoing detailed description should not be considered as a limitation of the scope of the present invention, which is limited only by the claims that may be drawn hereto.

Claims
  • 1. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said screen means and wound bed;a vacuum source fluidically communicating with said foam pad;a gas chromatograph, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, the gas chromatograph interposed between said foam pad and said vacuum source, wherein said gas chromatograph further comprises a photo diode to detect changes in light frequency as unfiltered wound fluid from the wound bed passes the photo diode;a computer-processing unit comprising a database that stores light frequencies associated with microorganisms;a software program operable to compare the light frequency detected by the gas chromatograph with the light frequencies stored in the database; anda collection canister interposed between said foam pad and said gas chromatograph.
  • 2. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said foam pad and wound bed;a vacuum source fluidically communicating with said foam pad;a flexible conduit for communicating between said foam pad and said vacuum source;a collection canister interposed between said foam pad and said vacuum source;a sensor array, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, interposed between said foam pad and said vacuum source, wherein said compositional characteristics are indicative of infection within the wound and include a presence of at least one of a bacterium or an antigen, wherein the sensor array comprises regions of nonconducting organic material, and wherein the sensor array further comprises regions of conducting organic material compositionally different than the nonconducting organic material; andwherein said sensor array is embedded within said foam pad.
  • 3. The negative pressure therapy device of claim 2 further comprising a flexible conduit for communicating between said foam pad and said vacuum source.
  • 4. The negative pressure therapy device of claim 1, wherein the microorganisms include at least one of a bacterium or an antigen.
  • 5. The negative pressure therapy device of claim 1, further comprising: a display operable to transmit at least one of an audible or visual notification if the software program identifies a match, between the light frequency detected by the gas chromatograph and at least one of the light frequencies stored in the database.
  • 6. The negative pressure therapy device of claim 1, further comprising: a filtration mechanism, the gas chromatograph interposed between the wound bed and the filtration mechanism.
  • 7. The negative pressure therapy device of claim 1, wherein said gas chromatograph is embedded within said foam pad.
  • 8. The negative pressure therapy device of claim 1, wherein said gas chromatograph is disposed on said drape, such that said gas chromatograph is in contact with said foam pad.
  • 9. The negative pressure therapy device of claim 1, wherein said gas chromatograph is disposed within said collection canister.
  • 10. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said foam pad and wound bed;a vacuum source fluidically communicating with said foam pad;a collection canister interposed between said foam pad and said vacuum source;a flexible conduit for communicating between said foam pad and said vacuum source;a gas chromatograph, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, the gas chromatograph interposed between said foam pad and said vacuum source, wherein said gas chromatograph further comprises a photo diode to detect changes in light frequency as unfiltered wound fluid from the wound bed passes the photo diode;a filtration mechanism, the gas chromatograph interposed between the wound bed and the filtration mechanism;a computer-processing unit comprising a database that stores light frequencies associated with microorganisms, wherein the microorganisms include at least one of a bacterium or an antigen;a software program operable to compare the light frequency detected by the gas chromatograph with the light frequencies stored in the database; anda display transmitting at least one of an audible or visual notification if the software program identifies a match between the light frequency detected by the gas chromatograph and at least one of the light frequencies stored in the database.
  • 11. The negative pressure therapy device of claim 10, wherein said gas chromatograph is embedded within said foam pad.
  • 12. The negative pressure therapy device of claim 10, wherein said gas chromatograph is disposed on said drape, such that said gas chromatograph is in contact with said foam pad.
  • 13. The negative pressure therapy device of claim 10, wherein said gas chromatograph is disposed within said collection canister.
  • 14. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said foam pad and wound bed;a vacuum source fluidically communicating with said foam pad;a flexible conduit for communicating between said foam pad and said vacuum source;a collection canister interposed between said foam pad and said vacuum source;a sensor array, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, interposed between said foam pad and said vacuum source, wherein said compositional characteristics are indicative of infection within the wound and include a presence of at least one of a bacterium or an antigen, wherein the sensor array comprises regions of nonconducting organic material, and wherein the sensor array further comprises regions of conducting organic material compositionally different than the nonconducting organic material; andwherein said sensor array is disposed on said drape, such that said sensor array is in contact with said foam pad.
  • 15. The negative pressure therapy device of claim 14 further comprising a flexible conduit for communicating between said foam pad and said vacuum source.
  • 16. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said foam pad and wound bed;a vacuum source fluidically communicating with said foam pad;a flexible conduit for communicating between said foam pad and said vacuum source;a collection canister interposed between said foam pad and said vacuum source;a sensor array, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, interposed between said foam pad and said vacuum source, wherein said compositional characteristics are indicative of infection within the wound and include a presence of at least one of a bacterium or an antigen, wherein the sensor array comprises regions of nonconducting organic material, and wherein the sensor array further comprises regions of conducting organic material compositionally different than the nonconducting organic material; andwherein said sensor array is disposed within said collection canister.
  • 17. The negative pressure therapy device of claim 16 further comprising a flexible conduit for communicating between said foam pad and said vacuum source.
  • 18. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said screen means and wound bed;a vacuum source fluidically communicating with said foam pad;a gas chromatograph, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, the gas chromatograph interposed between said foam pad and said vacuum source, wherein said gas chromatograph further comprises a photo diode to detect changes in light frequency as unfiltered wound fluid from the wound bed passes the photo diode;a computer-processing unit comprising a database that stores light frequencies associated with microorganisms;a software program operable to compare the light frequency detected by the gas chromatograph with the light frequencies stored in the database; anda filtration mechanism, the gas chromatograph interposed between the wound bed and the filtration mechanism.
  • 19. The negative pressure therapy device of claim 18, wherein the microorganisms include at least one of a bacterium, or an antigen.
  • 20. The negative pressure therapy device of claim 18, further comprising: a display operable to transmit at least one of an audible or visual notification if the software program identifies a match between the light frequency detected by the gas chromatograph and at least one of the light frequencies stored in the database.
  • 21. The negative pressure therapy device of claim 18, wherein said gas chromatograph is embedded within said foam pad.
  • 22. The negative pressure therapy device of claim 18, wherein said gas chromatograph is disposed on said drape, such that said gas chromatograph is in contact with said foam pad.
  • 23. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said screen means and wound bed;a vacuum source fluidically communicating with said foam pad;a gas chromatograph, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, the gas chromatograph interposed between said foam pad and said vacuum source, wherein said gas chromatograph further comprises a photo diode to detect changes in light frequency as unfiltered wound fluid from the wound bed passes the photo diode;a computer-processing unit comprising a database that stores light frequencies associated with microorganisms;a software program operable to compare the light frequency detected by the gas chromatograph with the light frequencies stored in the database; andwherein said gas chromatograph is embedded with said foam pad.
  • 24. The negative pressure therapy device of claim 23, wherein the microorganisms include at least one of a bacterium or an antigen.
  • 25. The negative pressure therapy device of claim 23, further comprising: a display operable to transmit at least one of an audible or visual notification if the software program identifies a match between the light frequency detected by the gas chromatograph and at least one of the light frequencies stored in the database.
  • 26. A negative pressure therapy device, comprising: a foam pad for placement within a wound bed;a drape adhered over said screen means and wound bed;a vacuum source fluidically communicating with said foam pad;a gas chromatograph, operable to sense compositional characteristics of unfiltered wound fluid from the wound bed, the gas chromatograph interposed between said foam pad and said vacuum source, wherein said gas chromatograph further comprises a photo diode to detect changes in light frequency as unfiltered wound fluid from the wound bed passes the photo diode;a computer-processing unit comprising a database that stores light frequencies associated with microorganisms;a software program operable to compare the light frequency detected by the gas chromatograph with the light frequencies stored in the database; andwherein said gas chromatograph is disposed on said drape, such that said gas chromatograph is in contact with said foam pad.
  • 27. The negative pressure therapy device of claim 26, wherein the microorganisms include at least one of a bacterium or an antigen.
  • 28. The negative pressure therapy device of claim 26, further comprising: a display operable to transmit at least one of an audible or visual notification if the software program identifies a match between the light frequency detected by the gas chromatograph and at least one of the light frequencies stored in the database.
RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. §119(e), of U.S. provisional patent application No. 60/273,587 filed Mar. 5, 2001.

US Referenced Citations (117)
Number Name Date Kind
1355846 Rannells Oct 1920 A
2547758 Keeling Apr 1951 A
2632443 Lesher Mar 1953 A
2682873 Evans et al. Jul 1954 A
2910763 Lauterbach Nov 1959 A
2969057 Simmons Jan 1961 A
3066672 Crosby, Jr. et al. Dec 1962 A
3367332 Groves Feb 1968 A
3520300 Flower Jul 1970 A
3568675 Harvey Mar 1971 A
3648692 Wheeler Mar 1972 A
3682180 McFarlane Aug 1972 A
3826254 Mellor Jul 1974 A
4080970 Miller Mar 1978 A
4096853 Weigand Jun 1978 A
4139004 Gonzalez Feb 1979 A
4165748 Johnson Aug 1979 A
4184510 Murry et al. Jan 1980 A
4233969 Lock et al. Nov 1980 A
4245630 Lloyd et al. Jan 1981 A
4256109 Nichols Mar 1981 A
4261363 Russo Apr 1981 A
4275721 Olson Jun 1981 A
4284079 Adair Aug 1981 A
4297995 Golub Nov 1981 A
4333468 Geist Jun 1982 A
4373519 Errede et al. Feb 1983 A
4382441 Svedman May 1983 A
4392853 Muto Jul 1983 A
4392858 George et al. Jul 1983 A
4419097 Rowland Dec 1983 A
4465485 Kashmer et al. Aug 1984 A
4475909 Eisenberg Oct 1984 A
4480638 Schmid Nov 1984 A
4525166 Leclerc Jun 1985 A
4525374 Vailancourt Jun 1985 A
4540412 Van Overloop Sep 1985 A
4543100 Brodsky Sep 1985 A
4548202 Duncan Oct 1985 A
4551139 Plaas et al. Nov 1985 A
4569348 Hasslinger Feb 1986 A
4605399 Weston et al. Aug 1986 A
4608041 Nielson Aug 1986 A
4640688 Hauser Feb 1987 A
4655754 Richmond et al. Apr 1987 A
4664662 Webster May 1987 A
4710165 McNeil et al. Dec 1987 A
4733659 Edenbaum et al. Mar 1988 A
4743232 Kruger May 1988 A
4758220 Sundblom et al. Jul 1988 A
4787888 Fox Nov 1988 A
4826494 Richmond et al. May 1989 A
4838883 Matsuura Jun 1989 A
4840187 Brazier Jun 1989 A
4863449 Therriault et al. Sep 1989 A
4872450 Austad Oct 1989 A
4878901 Sachse Nov 1989 A
4897081 Poirier et al. Jan 1990 A
4906233 Moriuchi et al. Mar 1990 A
4906240 Reed et al. Mar 1990 A
4919654 Kalt Apr 1990 A
4941882 Ward et al. Jul 1990 A
4953565 Tachibana et al. Sep 1990 A
4955391 Parker et al. Sep 1990 A
4969880 Zamierowski Nov 1990 A
4985019 Michelson Jan 1991 A
5037397 Kalt et al. Aug 1991 A
5039491 Saaski et al. Aug 1991 A
5086170 Luheshi et al. Feb 1992 A
5092858 Benson et al. Mar 1992 A
5100396 Zamierowski Mar 1992 A
5134994 Say Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5167613 Karami et al. Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5215522 Page et al. Jun 1993 A
5232453 Plass et al. Aug 1993 A
5237523 Bonne et al. Aug 1993 A
5261893 Zamierowski Nov 1993 A
5278100 Doan et al. Jan 1994 A
5279550 Habib et al. Jan 1994 A
5298015 Komatsuzaki et al. Mar 1994 A
5342376 Ruff Aug 1994 A
5344415 Debusk et al. Sep 1994 A
5358494 Svedman Oct 1994 A
5437184 Shillady Aug 1995 A
5437622 Carion Aug 1995 A
5437651 Todd et al. Aug 1995 A
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5556375 Ewall Sep 1996 A
5583281 Yu Dec 1996 A
5607388 Ewall Mar 1997 A
5611846 Overton et al. Mar 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5811255 Hunter et al. Sep 1998 A
5855570 Scherson et al. Jan 1999 A
6017440 Lewis et al. Jan 2000 A
6071267 Zamierowski Jun 2000 A
6120462 Hibner et al. Sep 2000 A
6135116 Vogel et al. Oct 2000 A
6188067 Chutjian et al. Feb 2001 B1
6190858 Persaud et al. Feb 2001 B1
6192753 Czarnek Feb 2001 B1
6241747 Ruff Jun 2001 B1
6345623 Heaton et al. Feb 2002 B1
6398767 Fleischmann Jun 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6493568 Bell et al. Dec 2002 B1
6553998 Heaton et al. Apr 2003 B2
6814079 Heaton et al. Nov 2004 B2
20020077661 Saadat Jun 2002 A1
20020115951 Norstream et al. Aug 2002 A1
20020120185 Johnson Aug 2002 A1
20020143286 Tumey Oct 2002 A1
Foreign Referenced Citations (29)
Number Date Country
550575 Aug 1982 AU
745271 Mar 2002 AU
755496 Dec 2002 AU
2005436 Jun 1990 CA
26 40 413 Mar 1978 DE
43 06 478 Sep 1994 DE
295 04 378 Sep 1995 DE
0117632 Jan 1984 EP
0100148 Feb 1984 EP
0161865 Nov 1985 EP
0358 302 Mar 1990 EP
1 018 967 Aug 2004 EP
692578 Jun 1953 GB
2 195 255 Apr 1988 GB
2 197 789 Jun 1988 GB
2 220 357 Jan 1990 GB
2 235 877 Mar 1991 GB
2333965 Aug 1999 GB
2329127 Aug 2000 GB
71559 Apr 2002 SG
WO 8002182 Oct 1980 WO
WO 8704626 Aug 1987 WO
WO 9010424 Sep 1990 WO
WO 9309727 May 1993 WO
WO9420041 Sep 1994 WO
WO 9605873 Feb 1996 WO
WO 9718007 May 1997 WO
WO 9913793 Sep 1998 WO
WO 0059424 Oct 2000 WO
Related Publications (1)
Number Date Country
20020143286 A1 Oct 2002 US
Provisional Applications (1)
Number Date Country
60273587 Mar 2001 US